Impact of Modern Low Dose Involved Site Radiation Therapy on Normal Tissue Toxicity in Cervicothoracic Non-Hodgkin Lymphomas: A Biophysical Study.

Lyman–Kutcher–Burman model involved site radiation therapy non-Hodgkin lymphoma normal tissue toxicity reduced radiation doses

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
05 Dec 2023
Historique:
received: 23 10 2023
revised: 29 11 2023
accepted: 01 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

This biophysical study aimed to determine fitting parameters for the Lyman-Kutcher-Burman (LKB) dose-response model for normal tissue complication probability (NTCP) calculations of acute side effects and to investigate the impact of reduced radiation doses on the probability of their occurrence in supradiaphragmatic non-Hodgkin lymphoma (NHL) irradiation. A cohort of 114 patients with NHL in the cervicothoracic region, treated between 2015 and 2021 at the University Hospitals of Münster, Hamburg, and Essen, with involved site radiation therapy (ISRT), were included. Among them, 68 patients with aggressive NHL (a-NHL) received consolidative radiation therapy with 24-54 Gy following (R-)CHOP chemotherapy. Additionally, 46 patients with indolent NHL (i-NHL) underwent radiotherapy with 22.5-45.0 Gy. Two treatment plans were prospectively created for each patient (a-NHL: 30.0/40.0 Gy; i-NHL: 24.0/30.0 Gy). NTCP were then calculated using the optimized LKB model. The adapted dose-response models properly predicted the patient's probability of developing acute side effects when receiving doses ≤ 50 Gy. In addition, it was shown that reduced radiation doses can influence the NTCP of acute side effects depending on the aggressiveness of NHL significantly. This study provided a foundation to prospectively assess the probability of adverse side effects among today's reduced radiation doses in the treatment of NHL.

Identifiants

pubmed: 38136257
pii: cancers15245712
doi: 10.3390/cancers15245712
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Julian Roers (J)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

Daniel Rolf (D)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

Andrea Baehr (A)

Department of Radiation Oncology, University Hospital of Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.

Christoph Pöttgen (C)

Department of Radiation Oncology, University Hospital of Essen, West German Cancer Center (WTZ), Hufelandstraße 55, 45147 Essen, Germany.

Martina Stickan-Verfürth (M)

Department of Particle Therapy, University Hospital of Essen, West German Proton Therapy Center Essen (WPE), West German Cancer Center (WTZ), Am Mühlenbach 1, 45147 Essen, Germany.

Jan Siats (J)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

Dominik A Hering (DA)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

Christos Moustakis (C)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.
Department of Radiation Oncology, University Hospital of Leipzig, Stephanstraße 9a, 04103 Leipzig, Germany.

Maximilian Grohmann (M)

Department of Radiation Oncology, University Hospital of Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.

Michael Oertel (M)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

Uwe Haverkamp (U)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

Martin Stuschke (M)

Department of Radiation Oncology, University Hospital of Essen, West German Cancer Center (WTZ), Hufelandstraße 55, 45147 Essen, Germany.

Beate Timmermann (B)

Department of Particle Therapy, University Hospital of Essen, West German Proton Therapy Center Essen (WPE), West German Cancer Center (WTZ), Am Mühlenbach 1, 45147 Essen, Germany.

Hans T Eich (HT)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

Gabriele Reinartz (G)

Department of Radiation Oncology, University Hospital of Münster, West German Cancer Center (WTZ) Network Partner Site, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

Classifications MeSH